Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property
Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced cocaine use in adults with cocaine use disorder over six months, with no serious adverse events Filament Health Corp., a wholly-owned subsidiary of Red Light Holland, holds the exclusive worldwide license to the trial data and certain associated intellectual property, with the goal of supporting future regulatory authoriza
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-08 7:30 AM EDT | Red Light Holland Corp.
Steep Hill Announces Consolidation and Name Change
Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Steep Hill Inc. (CSE: STPH) ("Steep Hill" or the "Company") is pleased to announce that, further to its press releases of November 13, 2025 and December 19, 2025, and in connection with its ongoing transaction with Good Purpose Investments Inc. ("Good Purpose"), the Company has filed articles of amendment (the "Articles"), to be effective May 12, 2026, to change its name to "Good Purpose Investments Inc." (the
Retail, Cannabis, Psychedelics, Cannabis Manufacturer
2026-05-07 6:05 PM EDT | Steep Hill Inc.
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-07 7:30 AM EDT | Red Light Holland Corp.
Steep Hill Announces Closing of Debt Settlement
Toronto, Ontario--(Newsfile Corp. - May 6, 2026) - Steep Hill Inc. (CSE: STPH) ("Steep Hill" or the "Company") is pleased to announce that, further to its press release of April 30, 2026, it has settled an aggregate of $79,278.00 of indebtedness to a non-arm's length creditors of the Company through the issuance of 1,321,300 common shares in the capital of the Company (the "Common Shares") at a price of $0.06 per Common Share (the "Debt Settlement").
Retail, Cannabis, Psychedelics, Cannabis Manufacturer
2026-05-06 5:15 PM EDT | Steep Hill Inc.
Red Light Holland Announces Intention to Rebrand
New name and branding to be announced in the coming weeks, better aligned with the Company's scientific mandate and all business segments Name change resolution to be voted on by shareholders at the upcoming Annual General and Special Meeting ("AGSM") on May 11, 2026 Company urges all shareholders to vote IN FAVOUR of the name change resolution to support the rebranding exercise Rebranding reflects the combined focus on clinical research, GMP
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-04 8:30 AM EDT | Red Light Holland Corp.
Adaptogenics Health Corp. Announces Strategic Review of Health & Wellness Opportunities and Management Changes
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") announces that its board of directors has initiated a strategic review to evaluate potential business opportunities within the broader health and wellness sector. As part of this review, the Company's board of directors and senior management are examining a range of potential strategic initiatives, which may include prospective b
Household / Consumer / Cosmetics, Psychedelics
2026-05-01 2:40 PM EDT | Adaptogenics Health Corp.
Neural Therapeutics Announces Filing and Mailing of Meeting Materials for Annual and Special Meeting to Approve Series B Transactions with CWE
Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, announces that it has filed on SEDAR+ and completed the mailing of its notice of annual and special meeting, management information circular and related meeting materials (collectively, the "Mee
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-01 8:04 AM EDT | Neural Therapeutics Inc.
Steep Hill Announces Debt Settlement
Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Steep Hill Inc. (CSE: STPH) ("Steep Hill" or the "Company") announces that it intends to settle an aggregate of $79,278.00 of indebtedness to a non-arm's length creditors of the Company through the issuance of 1,321,300 common shares in the capital of the Company (the "Common Shares") at a price of $0.06 per Common Share (the "Debt Settlement"). The Common Shares issued pursuant to the Debt Settlement
Retail, Cannabis, Psychedelics, Cannabis Manufacturer
2026-04-30 4:00 PM EDT | Steep Hill Inc.
Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution Adds Filament's extensive intellectual property portfolio, including 70+ patents and proprietary extraction technologies Leverages Health Canada Dealer's License and FDA-aligned clinical development pathways, including IND-enabled activities Positions the Company at the forefront of the rapidly emerging regu
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-30 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement
Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026, March 23, 2026 and April 27, 2026, that the Supreme Court of British Columbia has issued a final order (the "Final Order") approving the previously announced acquisition by Red Ligh
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-29 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Announces Filament Health Shareholder Approval of Acquisition
Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026 and March 23, 2026, Filament's shareholders (the "Filament Shareholders") have approved each of the matters voted on at the Filament annual general and special meeting ("Filament Meeting") hel
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-27 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and execution of clinical supply shipments of PEX010, a botanical psilocybin drug candidate developed by Filament Health Corp., to leading Canadian research institutions. Following its press release dated April 7, 2026, Red Light is highlighting recent accomplishments and ongoing momentum, including
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-24 8:26 AM EDT | Red Light Holland Corp.
Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector
Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, today highlights recent U.S. federal policy developments supporting psychedelic research and outlines the potential implications for the sector and the Company. Recent announcements by U.S. President Donald Trump include an exec
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-04-23 7:30 AM EDT | Psyched Wellness Ltd.
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that further to its press release dated March 16, 2026, it intends to complete a portion of its previously announced offering of common shares (the "Offering") in Canada pursuant to the Listed Issuer Financing Exemption c
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-04-23 7:00 AM EDT | Optimi Health Corp.
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Numinus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal agencies to accelerate research, access, and regulatory review for psychedelic-based treatments, including psilocybin, ibogaine, MDMA, and LSD. The Order directs the FDA to prioritize review of psychedelics with Breakthrough Therapy designation, establishes new investigational acces
2026-04-20 8:30 AM EDT | Numinus Wellness Inc.
Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate
Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of Washington Second psilocybin session showed meaningful improvements in anxiety, depression, and overall psychological outcomes, with effects lasting up to 24 weeks 69% of participants fell below clinical thresholds for anxiety and depression after second treatment Research builds on prior studies utilizing Filament's botanica
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-20 7:30 AM EDT | Red Light Holland Corp.
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine Initiative, a program to extend the Company's Health Canada-licensed GMP platform to include the manufacture and supply of ibogaine. The initiative comes as the United States has, for the first time, taken ini
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-04-20 6:00 AM EDT | Optimi Health Corp.
Optimi Health startet Ibogaine-Initiative, da US-Executive Order einen Weg für psychedelische Arzneimittelprodukte signalisiert
Vancouver, British Columbia--(Newsfile Corp. - Montag, 20. April 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein kommerziell tätiger pharmazeutischer Hersteller regulierter psychedelischer Arzneimittelprodukte, gab heute den Start seiner Ibogaine-Initiative bekannt. Ziel des Programms ist es, die nach GMP lizenzierte Plattform des Unternehmens mit Health-Canada-Zulassung auf die Herstellung und Lieferung von Ibogaine auszuwe
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-04-20 2:00 AM EDT | Optimi Health Corp.
Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments
Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that Filament Health Corp. ("Filament") signed three new license agreements and completed two research shipments during March 2026, further expanding the global cl
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-07 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that, through Filament Health Corp. ("Filament"), it will support the Carhart-Harris Lab ("CHL") at the University of California, San Francisco ("UCSF") by providing instructions on how to participate in the CHL Global Psychedelic Study to all researchers and clinicians receiving PEX010, including clinical trials and compassionate us
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-01 9:20 AM EDT | Red Light Holland Corp.